MRK’s BACE Inhibitor for AD fails in mild-to-moderate phase-3 trial; prodromal phase-3 continues with likely readout in 2019: http://investors.merck.com/news/press-release-details/2017/Merck-Announces-EPOCH-Study-of-Verubecestat-for-the-Treatment-of-People-with-Mild-to-Moderate-Alzheimers-Disease-to-Stop-for-Lack-of-Efficacy/default.aspx